Abstracts tagged "COVID-19"

Abstract Number: 1553 • ACR Convergence 2021
Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up
Lauren He¹, Garth Strohbehn² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²VA Ann Arbor Center for Clinical Management and Research, Chicago, IL, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Tocilizumab (TCZ) for treatment of severe coronavirus disease 2019 (COVID-19) pneumonia decreases the probability of progression to invasive mechanical ventilation (CORIMUNO-TOCI) or death (REMAP-CAP,…
Abstract Number: 1594 • ACR Convergence 2021
COVID-19 Pandemic-Related Changes in Health Routines and Self-Reported Physical Functioning Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim³ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic was disruptive to individual health routines. Changes in health routines may worsen disease management and reduce opportunities for physical activity, both…
Abstract Number: 1612 • ACR Convergence 2021
Factors Associated with COVID-19 Vaccine Hesitancy Among Individuals with Rheumatic Disease
Kristin Wipfler¹, Adam Cornish¹, Alison Freifeld², Patricia Katz³ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of California San Francisco, San Francisco, CA
Background/Purpose: COVID-19 vaccination efforts are ongoing and there is a need to understand factors associated with vaccine hesitancy. Individuals with rheumatic diseases have been uniquely…
Abstract Number: 1928 • ACR Convergence 2021
In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

Randy Cron¹, Mingce Zhang¹, Niansheng Chu², Devin Absher³, John Bridges¹, Amanda Schnell¹, Anshul Vagrecha⁴, Shannon Lozinsky⁴, Suchitra Acharya⁴, Carolyn Levy⁴, Winn Chatham¹ and Edward Behrens², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL, ⁴Hofstra/Northwell School of Medicine, Hempstead, NY
Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous missense…
Abstract Number: L01 • ACR Convergence 2020
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Naomi Serling-Boyd¹, Kristin D'Silva¹, Tiffany Hsu², Xiaoqing Fu³, Rachel Wallwork⁴, April Jorge¹, Yuqing Zhang¹, Ellen Gravallese⁵, Hyon K. Choi⁶, Jeffrey Sparks⁷ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Mass General Hospital, Boston, MA, ⁴Johns Hopkins Hospital, Baltimore, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of poor outcomes from COVID-19 among rheumatic disease patients compared to the general population remains poorly understood. Filling this knowledge gap is…
Abstract Number: L02 • ACR Convergence 2020
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
Mark Yates¹, Satveer Mahil¹, Sinead Langan², Claudia De la cruz³, Paola diMeglio¹, Nick Dand¹, Zenas Yiu⁴, Kayleigh Mason⁴, Teresa Tsakok¹, Freya Meynall⁵, Helen McAteer⁶, John Weinman¹, Paolo Gisondi⁷, Luis Puig Sanz⁸, Richard Warren⁴, Francesca Capon¹, Jullien Denis⁹, Tiago Torres¹⁰, Chris Griffiths⁴, Jonathan Barker¹, Kimme Hyrich⁴, Andrew Cope¹, Ian Bruce⁴, Iain McInnes¹¹, Raj Sengupta¹², Helena Marzo-Ortega¹³, Matthew Brown¹, James Galloway¹ and Catherine Smith¹, ¹King's College London, London, United Kingdom, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University of Santiago, Santiago, Chile, ⁴University of Manchester, Manchester, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁶Psoriasis Association, London, United Kingdom, ⁷University of Verona, Verona, Italy, ⁸Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁹Hospices Civils de Lyon, Lyon, France, ¹⁰University of Porto, Porto, Portugal, ¹¹University of Glasgow, Glasgow, United Kingdom, ¹²Royal United Hospitals Bath, Bath, United Kingdom, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinician-reported registry data suggest that use of biologics in people with immune-mediated inflammatory diseases (IMIDs) is associated with a lower risk of adverse COVID-19…
Abstract Number: L05 • ACR Convergence 2020
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Kaleb Michaud¹, Sofia Pedro², Kristin Wipfler³, Ekta Agarwal⁴ and Patricia Katz⁵, ¹University of Nebraska Medical Center and Forward, the National Databank for Rheumatic Diseases, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Pfizer inc, Princeton Jct, NJ, ⁵UCSF, Mill Valley, CA
Background/Purpose: To understand medication and clinical care changes by patients with RA during the first 3 months (March through May 2020) of the COVID-19 pandemic…
Abstract Number: L07 • ACR Convergence 2020
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
John Stone¹, ¹Massachusetts General Hospital, Boston, MA
Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Kristin Wipfler¹, Yomei Shaw², Teresa Simon³, Adam Cornish¹, Bryant England⁴, Alexis Ogdie⁵, Patricia Katz⁶ and Kaleb Michaud⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, ³Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, Novato, CA
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…
Abstract Number: 0429 • ACR Convergence 2020
Prothrombotic Antiphospholipid Antibodies in COVID-19
Yu Zuo¹, Shanea Estes², Alex Ghandi³, Srilakshmi Yalavarthi³, Ramadan Ali³, Shi Hui³, Gautam Sule³, Kelsey Gockman³, Jacqueline Madison³, Melanie Zuo³, Wrenn Woodard³, Sean Lezak³, Njira Lugogo³, Yogendra Kanthi⁴ and Jason Knight¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombosis of arteries and veins. At the same time, COVID-19 lung histopathology has…
Abstract Number: 0578 • ACR Convergence 2020
Going Digital Due to COVID 19 Crisis: A Rapid Reorganisation of Medication Clinics
Rian Penford¹, Angela Reith¹, Elaine Wren¹ and Kirsten Mackay¹, ¹Torbay and South Devon NHS Foundation Trust, Torquay, United Kingdom
Background/Purpose: Until the COVID 19 crisis we initiated DMARD(s) and Biologic therapies using shared medical clinics. More than 30 patients could seen per week, with…
Abstract Number: 0633 • ACR Convergence 2020
Vitamin D Serum Status in a Cohort of COVID-19 Patients
Alberto Sulli¹, Emanuele Gotelli¹, Sabrina Paolino¹, Andrea Casabella¹, Carmen Pizzorni¹, Elisa Alessandri¹, Vanessa Smith² and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium
Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
Abstract Number: 1274 • ACR Convergence 2020
COVID-19 in Patients with Systemic Lupus Erythematosus
Ruth Fernandez-Ruiz¹, Mala Masson¹, Mimi Kim², Benjamin Myers³, Rebecca Haberman⁴, Jose Scher⁴, Rochelle Castillo⁴, Allison Guttmann¹, Philip Carlucci¹, Kristina Deonaraine¹, Michael Golpanian⁵, Kimberly Robins¹, Miao Chang¹, H. Michael Belmont⁶, Jill Buyon⁷, Ashira Blazer⁶, Amit Saxena⁸ and Peter Izmirly⁹, ¹New York University School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, ³Cornell University, Ithica, NY, ⁴NYU School of Medicine, New York City, ⁵New York University, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY, ⁸NYU School of Medicine, New York, ⁹Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…
Abstract Number: 1604 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Rheumatology Practice: A Study in 15 Arab Countries
Nelly Ziade¹, Ihsane Hmamouchi², Lina El Kibbi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Fatemah Abutiban⁶, Wafa Hamdi⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ³Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁷Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To date, information about the impact of the Coronavirus Disease (COVID-19) pandemic on rheumatology practice and on rheumatologists is limited.The primary objective of the…
Abstract Number: 0013 • ACR Convergence 2020
Colchicine to Weather the Storm in Hospitalized Patients with COVID-19
Luigi Brunetti¹, Oumou Diawara¹, Andrew Tsai², Bonnie Firestein³, Ronald Nahass⁴, George Poiani⁵ and Naomi Schlesinger⁶, ¹Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, ²Center of Excellence in Pharmaceutical Translational Research and Education, piscataway, NJ, ³Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, piscataway, NJ, ⁴Robert Wood Johnson University Hospital Somerset, somerset, NJ, ⁵Rutgers Robert Wood Johnson Medical School, somerset, NJ, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection, is a global pandemic causing havoc. There is a knowledge gap regarding…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].